Scholarlink

Background <p>Locally advanced penile squamous cell carcinoma (PSCC) generally has a poor prognosis. Our aim was to access the efficacy and safety of programmed cell death protein 1 (PD-1) inhibitor tislelizumab combined with chemotherapy for locally advanced PSCC.</p> Methods <p>In this prospective, single-arm clinical study, eligible patients received Nab-Paclitaxel (175 mg/m2 D1), Cisplatin (70 mg/m<sup>2</sup> in 3 days), Bleomycin (30 mg D1, 8), and tislelizumab (200 mg D1) every 3 weeks for 4–6 cycles, followed by consolidative treatment if necessary. The primary endpoint was objective response rate (ORR) and progression-free survival (PFS).</p> Results <p>Of all 20 enrolled patients, 75.0% (15/20) had a history of previous penectomy and were recurrence cases. The median treatment cycles was 4 (range: 2-6). The ORR reached 75.0%. 35.0% (7/20) of patients underwent consolidative surgery, and 55.0% (11/20) received maintenance immunotherapy (median 7 cycles). At median follow-up of 29.3 months, the median PFS and the median overall survival (OS) were 12.5 months (95% CI 7.4-NE), 22.8 months (95% CI 13.7-NE), respectively. Grade≥3 treatment-related adverse events (TRAEs) were observed in 40% (8/20) patients. No treatment-related deaths occurred.</p> Conclusions <p>The combination of tislelizumab with chemotherapy demonstrated promising antitumor efficacy in locally advanced PSCC, with a manageable safety profile.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of tislelizumab combined with chemotherapy for locally advanced penile cancer: a prospective, single-arm clinical study

  • 期刊论文

  • 发表日期：

    2025年12月26日

查看全文
  • Xingli Shan,
  • Hongsong Bai,
  • Houshan Ning,
  • Chengming Xie,
  • Yonghai Chen,
  • Sijia Xing,
  • Donglin Ni,
  • Xiaohua Guo,
  • Jingke Zeng,
  • Linjun Hu

摘要

Background

Locally advanced penile squamous cell carcinoma (PSCC) generally has a poor prognosis. Our aim was to access the efficacy and safety of programmed cell death protein 1 (PD-1) inhibitor tislelizumab combined with chemotherapy for locally advanced PSCC.

Methods

In this prospective, single-arm clinical study, eligible patients received Nab-Paclitaxel (175 mg/m2 D1), Cisplatin (70 mg/m2 in 3 days), Bleomycin (30 mg D1, 8), and tislelizumab (200 mg D1) every 3 weeks for 4–6 cycles, followed by consolidative treatment if necessary. The primary endpoint was objective response rate (ORR) and progression-free survival (PFS).

Results

Of all 20 enrolled patients, 75.0% (15/20) had a history of previous penectomy and were recurrence cases. The median treatment cycles was 4 (range: 2-6). The ORR reached 75.0%. 35.0% (7/20) of patients underwent consolidative surgery, and 55.0% (11/20) received maintenance immunotherapy (median 7 cycles). At median follow-up of 29.3 months, the median PFS and the median overall survival (OS) were 12.5 months (95% CI 7.4-NE), 22.8 months (95% CI 13.7-NE), respectively. Grade≥3 treatment-related adverse events (TRAEs) were observed in 40% (8/20) patients. No treatment-related deaths occurred.

Conclusions

The combination of tislelizumab with chemotherapy demonstrated promising antitumor efficacy in locally advanced PSCC, with a manageable safety profile.